Clinical evidence of thiazolidinedione‐induced improvement of pancreatic β‐cell function in patients with type 2 diabetes mellitus
- 1 January 2002
- journal article
- clinical trial
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 4 (1) , 56-59
- https://doi.org/10.1046/j.1463-1326.2002.00183.x
Abstract
Background: There is growing evidence in animal and in vitro studies showing that thiazolidinediones (TZDs) improve pancreatic beta cell (β‐cell) function. The aim of this study was to evaluate the effect of thiazolidinediones on the β‐cell function of patients with Type 2 diabetes mellitus (T2DM) in clinical practice.Patients and Methods: This is an observational, nested case‐control study. We identified 28 patients (TZD group), with T2DM, who had had a meal‐stimulated C‐peptide level documented before the addition of troglitazone to a failing double‐therapy regimen with metformin (MET) and sulphonylurea (SU). As a control group (CTRL), we identified 26 patients, with T2DM, who also had had a meal‐stimulated C‐peptide documented before adding MET to a failing SU monotherapy regimen. We then proceeded to prospectively remeasure their meal‐stimulated C‐peptide levels and compared the changes over time between the two groups.Results: Both groups were well matched for age, body mass index (BMI), and HgbA1c before and after treatment. The C‐peptide in the TZD group increased significantly during therapy (from 3.2 ± 0.5 to 4.2 ± 0.5, p = 0.01), whereas it remained unchanged in the CTRL group (from 4.8 ± 0.6 to 5.0 ± 0.5, p = 0.74). The C‐peptide/glucose ratio also increased significantly in the TZD group (from 1.9 ± 0.3 to 3.1 ± 0.3, p = 0.0003) whereas it remained unchanged in the CTRL group (from 3.4 ± 0.7 to 3.4 ± 0.3, p = 0.97). Furthermore, the C‐peptide/glucose ratio of the TZD group, which was significantly lower at baseline compared with the CTRL group (1.9 ± 0.3 vs. 3.4 ± 0.7, p = 0.04), caught up to its level during treatment (3.1 ± 0.3 vs. 3.4 ± 0.3, p = 0.48).Conclusion: Thiazolidinediones seem to induce recovery of pancreatic beta cell function, independently of the correction of glucose toxicity.Keywords
This publication has 10 references indexed in Scilit:
- Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 1998
- Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 1998
- Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes MellitusAnnals of Internal Medicine, 1998
- Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity.Journal of Clinical Investigation, 1997
- Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.Journal of Clinical Investigation, 1997
- Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazoneAmerican Journal of Physiology-Endocrinology and Metabolism, 1996
- Inhibitory effects of fatty acids on glucose-regulated b-cell function: Association with increased islet triglyceride stores and altered effect of fatty acid oxidation on glucose metabolismMetabolism, 1996
- Prevention of diabetes does not completely prevent insulin secretory defects in the ZDF ratAmerican Journal of Physiology-Endocrinology and Metabolism, 1995
- Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamideDiabetologia, 1995
- Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in miceMetabolism, 1991